We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA NEEDS PLAN TO MONITOR POTENTIAL DRUGS OF ABUSE
FDA NEEDS PLAN TO MONITOR POTENTIAL DRUGS OF ABUSE
January 30, 2004
The FDA’s guidance on risk management plans (RMPs) for controlled substances that could be categorized by the Drug Enforcement Administration (DEA) as schedule II drugs should encourage manufacturers submitting new drug applications to include plans for monitoring their use and identifying potential abuse and diversion problems, according to the General Accounting Office (GAO).